EGFR and non-small cell lung carcinoma: The study also found that the activity of Notch3 is also necessary in the evolution of the refractory treatment of EGFR mutant NSCLC, which has been identified as the substrate of EGFR-mediated tyrosine phosphorylation, and inhibiting EGFR activity will reduce tyrosine phosphorylation, thus enhancing Notch3 activity (21).